fda pulls semaglutide is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA Ban on Compounded GLP-1

According to the Centers for Disease Control and Prevention (CDC) data from 2023, over 37 million adults in the United States have diabetes, and the prevalence of obesity is also significantly high

When one of these medications goes off patent, the branded medication shares will decline, because incremental improvements in efficacy or tolerability will not be enough to convince price-sensitive consumers or insurers or healthcare systems to fork over a premium when theres a good enough semaglutide for $60, versus a $6,000 retatrutide

The MMIT GLP-1 guide provides additional market context

Super Powered Weight Loss While magazine articles and TV ads laud these injections as a highly complex, modern miracle for weight loss, the science that powers this medication is actually very simple

DSIP is not FDA-approved for any indication